Cefamandole nafate, a new cephalosporin for parenteral use, was evaluated in vitro against 231 recent clinical isolates and in 12 patients. Cefamandole had activity equivalent to cefazolin against Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae. Cefamandole was more active than cephalothin or cefazolin against Proteus mirabilis. Both cefamandole and cefazolin were as active as cephalothin against S. aureus, were slightly more active against K. pneumoniae, and were considerably more active against E. coli. All strains of indolepositive Proteus sp. were inhibited by 6.3 ,ug of cefamandole per ml but only 20%o were inhibited by 25 ,ug of cefazolin or cephalothin per ml. Eighty-eight percent of Enterobacter sp. was inhibited by 25 ug of cefamandole per ml, but only 20 and 5% were inhibited by the same concentration of cefazolin and cephalothin, respectively. Peak levels of cefamandole ranged from 6.0 to 110 ,ug/ml in serum and levels ranged from 440 to 16,800 ,ug/ml in a 4-to 6-h collection of urine after a 500-mg or 1-g intramuscular dose (6.1 to 17.3 mg/kg) in patients with endogenous creatinine clearances of .31 ml/min. These levels were done after the first dose, at mid-therapy, and at the end of therapy. There was no evidence of accumulation with the 500-mg or 1-g dose given every 4 to 6 h. The percentage of the dose excreted in the urine within the first 4 to 6 h after administration of eefamandole was -43%. The half-life of cefamandole in serum was 49 to 126 min.
Cefamandole nafate, the sodium salt of the O-formyl ester of cefamandole, 7-D-mandelamido-3 -{[(1 -methyl -1H -tetrazol -5-yl)thiomethyl}-3-cephem4-carboxylic acid, is a new cephalosporin antibiotic for parenteral use. The ester undergoes rapid hydrolysis to cefamandole in vivo (J. S. Wold, R. R. Joost, H. R. Black, and K. E. Briscoe, Abstr. 9th Int. Congr. Chemother. M225, 1975) . Cefamandole is bactericidal against strains of gram-positive and gram-negative bacteria including Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, as are other cephalosporin antibiotics (3, 7, 10) . Unlike cephalothin, cefamandole has been reported to be also active against Enterobacter sp. and indole-positive Proteus sp. (3, 7, 10) .
The present investigation was undertaken to determine the in vitro antibacterial activity of cefamandole in comparison with cefazolin and cephalothin, and to determine the levels of cefamandole in serum and urine in patients after intramuscular administration.
MATERIALS AND METHODS
In vitro susceptibility tests. The following strains of bacteria were isolated from patients: 49 strains of S. aureus, 50 strains of E. coli, 28 strains of P. mirabilis, 49 strains ofK. pneumoniae, 15 strains of indole-positive Proteus species, and 40 strains of Enterobacter species.
The susceptibility of the organisms to cefamandole lithium, cefazolin sodium, and cephalothin sodium was determined by an agar-dilution method in heart infusion agar at pH 7.4. The lithium salt of cefamandole .was used in preference to the sodium salt because of its greater stability; both salts are reported to have equal antimicrobial activity (R. B. Kammer, D. A. Preston, and J. R. Turner, 9th Int. Congr. Chemother. M226, 1975) . The antibiotics were diluted in twofold steps in heart infusion broth. One milliliter of each dilution of antibiotic was added to 9 ml of molten agar to obtain final antibiotic concentrations of 0.098 to 50 ,ug/ml. Bacteria were inoculated onto the surface of these plates using the replicating device of Steers et al. (9) . The replicator delivered approximately 0.001 ml of a 10-1 dilution of an overnight culture (105 bacteria) of each strain in heart infusion broth. The minimal inhibitory concentration was considered to be the lowest concentration of antibiotic that prevented more than one colony from growing after 24 h of incubation at 37 C. Susceptibility to a 10-jg ampicillin disk was done by the Bauer-Kirby technique (1).
Determination of antibiotic concentrations in serum and urine. Serum and urine concentrations of cefamandole were determined during 1 to 40 days of therapy in 12 patients treated for a variety of acute infections with cefamandole nafate. Cefamandole nafate was administered intramuscularly in a dosage of 0.5 or 1.0 g (dissolved in 2 and 4 ml of sterile water, respectively) every 4 to 6 h. Blood was obtained 0.5, 1, 2, 3, 4, 5, and 6 h after administration of a dose of cefamandole nafate. Urine specimens were obtained by having the patient void before receiving a dose of cefamandole and collecting urine voided during and at the end of the following 4-or 6-h interval. Serum was separated and stored at -20 C until the time of assay. Urine was stored at -20 C. The concentrations assayed as cefamandole lithium in serum and urine were determined by a modification of the agar diffusion method with the use of paper disks (9) . Levels of cefamandole in serum decreased linearly after the peak when the logarithms of the concentrations were plotted against time. The half-life (t12) in serum was calculated by the method of least squares (6) .
RESULTS AND DISCUSSION
In vitro antibacterial activity of cefamandole lithium and comparison with cefazolin sodium and cephalothin sodium. All strains of S. aureus were inhibited by 1.6 pg of cefamandole, cefazolin, and cephalothin per ml ( Fig. 1 ). Cefazolin and cefamandole had equivalent in vitro activity against E. coli. Both antibiotics inhibited over 90%o of strains of E. coli at 12.5 ,ug/ml and all strains, at 50 jug/ml (Fig. 2) .
However, 44% of strains ofE. coli were resistant to 12.5 pg of cephalothin per ml and 24% were resistant t,o 50 ug/ml. Of the 12 strains ofE. coli resistant to 59 pug of cephalothin per ml, 10 were susceptible to 6.3 ,ug of cefamandole per ml and 11 were susceptible to the same concentration of cefazolin. Ten of the 50 E. coli strains were resistant by disk-sensitivity testing to ampicillin. Five of the 10 ampicillin-resistant strains were resistant to 12.5 pg of cefamandole per ml, 2 strains to 12.5 pg of cefazolin per ml, and 6 to 12.5 pg of cephalothin per ml. All strains ofP. mirabilis were inhibited by 6.3 pg of cefamandole per ml, 12.5 pg of cephalothin per ml, and 25 pg of cefazolin per ml (Fig. 3) .
All strains ofK. pneumoniae were inhibited by 6.3 pg of cefazolin per ml, 12.5 pg of cefamandole per ml, and 25 pg of cephalothin per ml (Fig. 4) .
Of particular interest was the inhibition of certain indole-positive Proteus sp. and Enterobacter sp. by cefamandole, in contrast to the relative resistance of these strains to cefazolin and cephalothin. All strains of indole-positive Proteus sp. (two strains of P. rettgeri, five strains of P. morganii, and eight strains of P. vulgaris) were inhibited by 6.3 pg of cefamandole per ml, whereas only 20% were inhibited by 25 pg of cefazolin or cephalothin per ml (Fig. 5) . Eight-eight percent of Enterobacter sp. was inhibited by 25 pg of cefamandole per ml, but only 20 and 5% by the same concentration of cefazolin or cephalothin (Fig. 6) . Inhibition of certain Enterobacter sp. and indole-positive Proteus sp. confirms previous studies (3, 6, 9) , which attributed this greater activity to increased stability of cefamandole to cephalosporinase activity (6, 9 cefamandole per kg intramuscularly (Fig. 7 ). 15.5 12. and not measurable (i.e., of the four patients. _ <0.6 pglml) in three
After an 11-to 17-mg/kg dose in nine patients, the peak serum concentrations ranged from 13.8 to 110 /hg/ml and occurred at 0.5 to 2 h after administration. The mean serum cefamandole concentration +1 standard deviation was 31.0 + 17.8 pg/ml at 0.5 h, 27.5 + 14.4 Ag/ml at 1 h, 16.1 4.8 ,ug/ml at 2 h, 9.7 4.0 pAg/ml at 3 h, 5.5 3.3 ,ug/ml at 4 h, 3.5-± 2.3 pg/ml at 5 h, and 1.7 ± 0.7 pg/ml at 6 h after 11 to 17 mg/kg intramuscularly (Fig. 7) . With repeated dosing, there was no evidence of drig accumulation. Urine concentrations of cefamandole ranged from 440 to 16,800 yg/ml, and at least 43% was excreted in a 4-to 6-h period after drug administration. 
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Serum t12 was 49 to 126 min, which is longer than that reported for cefoxitin (2) and cephalothin (5), similar to cephaloridine (4, 5), but shorter than cefazolin (6) . When cefamandole serum t12, as a geometric function, was plotted against creatinine clearance, as a linear function, the slope of this line was 0.0, calculated by the method of least squares (6) : there was no relation between endogenous creatinine clearances 231 ml/min and serum t12. Six of the patients had bacterial infections confirmed by culture (S. pneumoniae pneumonia, three patients; S. aureus pneumonia, one patient; Haemophilus influenzae pneumonia, one patient; and Staphylococcus epidermidis endarteritis after aortotomy, one patient) were cured. Intramuscular administration of cefamandole nafate was well tolerated; only one patient complained of pain at the site of intramuscular injection. Diarrhea, which ceased at the end of cefamandole therapy, occurred in one patient. One patient with pneumonia and glucose-6-phosphate dehydrogenase deficiency had a fall in hematocrit from 37 to 18.6% after 2 weeks of therapy. Subsequently, incubation ofher erythrocytes in vitro in the presence of up to 100 ug of cefamandole per ml failed to induce Heinz body formation. Two patients developed mild eosinophilia. Two patients developed a rise in creatine phosphokinase and serum glutamic oxalacetic transaminase, perhaps associated with intramuscular cefamandole administration. Another patient developed a transient mild rise in alkaline phosphatase, serum glutamic oxalacetic transaminase and serum glutamic pyruvic transaminase.
